Introduction and background {#Sec1}
===========================

Small intestinal bacterial overgrowth (SIBO) is a heterogeneous disorder with a clinical presentation ranging from florid malabsorption to minor, non-specific or an absence of symptoms \[[@CR1]\]. SIBO is commonly defined as the presence of at least 1 × 10^5^ colony forming units of bacteria per milliliter in a duodenal aspirate \[[@CR2]\]. Although classically associated with motility disorders and anatomical abnormalities of the upper gastrointestinal tract, SIBO may be more prevalent than previously thought. This increased prevalence may be due to the availability of noninvasive, inexpensive and easily applicable alternative diagnostic test to direct assay of a duodenal aspirate, such as the lactulose-hydrogen breath test (LBT) \[[@CR3]\]. Furthermore, LBT testing allows for serial testing and provides an objective measure of treatment response. Indeed, normalization of the LBT correlates with symptom improvement in IBS patients \[[@CR4]\]. Antibiotics are the mainstay of treatment for SIBO. Minimally-absorbed antibiotics, such as rifaximin, offer a theoretical advantage by allowing maximal luminal activity with few systemic adverse effects. Nevertheless, the efficacy of such treatment, as measured by LBT negativity, varies greatly in the reported literature, ranging from 2% to 91% \[[@CR5],[@CR6]\].

Several studies have assessed rifaximin in patients with SIBO and IBS \[[@CR7]-[@CR10]\]. A recent meta-analysis found that 4-64% of IBS subjects may have a positive diagnostic test suggestive of SIBO. There is controversy whether such IBS patients should be diagnosed as IBS, or rather considered as SIBO, since the symptoms of IBS and SIBO overlap \[[@CR11]\]. Given the ambiguity surrounding the etiological role of SIBO in IBS patients, and given the fact that rifaximin may be beneficial for the treatment of IBS even in the absence of SIBO \[[@CR12]\], it follows that in order to assess the efficacy of rifaximin for the treatment of SIBO, a homogenous cohort of patients *without* IBS should be used. This is the first study to assess the efficacy of rifaximin in a non-IBS cohort. The rationale for treating SIBO in non-IBS subjects stems from the significant correlation observed between clinical symptoms related to SIBO and abnormal diagnostic tests \[[@CR13]\].

Aim {#Sec2}
---

The aim of this study is to assess the efficacy of rifaximin for the treatment of SIBO in non-IBS subjects, in our geographical region.

Materials and methods {#Sec3}
=====================

Patient eligibility {#Sec4}
-------------------

Between January 2012 and July 2013 consecutive patients over 18 years-old, presenting to the neurogastroenterology clinic at our institution with primary symptoms of bloating and flatulence, were prospectively recruited, and subjected to LBT. None of the subjects complained of chronic recurrent abdominal pain or fulfilled the Rome III criteria for irritable bowel syndrome \[[@CR14]\].

Patients who used antibiotics during the previous 6 months, currently used laxatives or promotility agents, or had received bowel preparation for colonoscopy or capsule endoscopy within 30 days, were excluded. Additional exclusion criteria were presence of pancreatic exocrine insufficiency or major concomitant diseases (including active malignancy, hepatic failure and renal insufficiency), hypersensitivity to antibiotics belonging to the rifamycin and/or tetracyclin families, patient unwillingness or inability to provide informed consent, and patient inability to fully complete all phases of the study. Finally, we excluded pregnant and lactating women, as well as premenopausal women not using contraception.

The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice (GCP) and was approved by the Human Subjects Protection Program of Rabin Medical Center.

Clinical assessment {#Sec5}
-------------------

Prior to LBT, all patients were assessed at a dedicated neurogastroenterology clinic by a study physician (RD) for a thorough clinical assessment and to confirm the absence of IBS. Following LBT patients returned to the study physician for rifaximin prescription and continued to be monitored on an individualized basis. Symptoms were monitored at clinic visits which were scheduled fortnightly.

Rome III diagnostic questionnaire for irritable bowel syndrome {#Sec6}
--------------------------------------------------------------

This self-assessed standardized and validated questionnaire was developed by the Rome Foundation Board to identify functional gastrointestinal disease. For the diagnosis of IBS, patients must have recurrent abdominal pain or discomfort for at least 3 months in the previous 6 months, with 2 or more of the following symptoms: (1) relief with defecation, (2) onset associated with a change in frequency of stool, and (3) onset associated with a change in form (appearance) of stool. All screened subjects completed a validated Hebrew language Rome III Diagnostic Questionnaire for IBS \[[@CR14]\]. Only patients that did not fulfill the Rome III criteria for IBS were included and were offered treatment with rifaximin.

SIBO Evaluation {#Sec7}
---------------

LBT was performed according to standard protocols \[[@CR15]\]. Each subject was submitted to LBT (EC 60 Gastrolyzer 2, Bedfont Scientific, Rochester, UK) following a 3 day low carbohydrate diet, overnight fasting, and chlorhexidine mouthwash. Samples of end-expiratory air were collected before oral administration of 15 g lactulose diluted in 400 mL of water, every 15 min for 90 minutes (15, 30, 45, 60, 75, 90 minutes). The accuracy of the Gastrolyzer was ±2% of reading. The sensor sensitivity was 1 ppm. The test was considered positive for SIBO when an increase over the baseline level was \>10 ppm, on the basis of established validation data \[[@CR16],[@CR17]\].

SIBO Eradication {#Sec8}
----------------

Non-IBS patients with a positive LBT received treatment with rifaximin 1200 mg daily for 10 days (Normix, Alfa Wassermann, Italy). Patients were reassessed with LBT two weeks after completion of treatment.

Statistical analysis {#Sec9}
--------------------

All analyses were performed using SPSS version 21.0 statistical analysis software (IBM Inc, Chicago, IL, USA). Distributions of continuous variables were assessed for normality using the Kolmogorov-Smirnov test (cutoff at p \< 0.1). Distributions of all continuous variables deviated significantly from normal so were described as median (min-max) in addition to mean ± standard deviation. Continuous variables were compared by rifaximin treatment exposure using the student\'s t-test. Nominal variables were described as frequency counts and presented as n(%). Nominal variables were compared using the chi square test. We calculated that at least 22 patients needed to be recruited in order to have a 90% chance of detecting a 50% rate of breath test normalization following treatment with rifaximin. All tests were two-sided and considered significant at p \< 0.05.

Results {#Sec10}
=======

Demographics {#Sec11}
------------

A total of 53 non-IBS patients underwent LBT of whom 22 patients (41.5%) had a positive LBT result. All patients were offered primary treatment with rifaximin (1200 mg daily for 10 days). 3 patients who received rifaximin did not undergo follow-up LBT, and therefore 19 patients (7 (36.8%) males, aged 56.5 ± 17.6 years) were included in the final set analysis (Figure [1](#Fig1){ref-type="fig"}).Figure 1**Study Flowchart.**

Clinical characteristics {#Sec12}
------------------------

The clinical characteristics of patients receiving rifaximin for SIBO are shown in Table [1](#Tab1){ref-type="table"}. Among the 19 non-IBS patients receiving rifaximin for treatment of LBT-diagnosed SIBO, 13 (68.4%) received antisecretory therapy, 5 (26.3%) reported diabetes mellitus and 2 patients reported collagen vascular disease.Table 1**Characteristics of patients receiving rifaximin for small intestine bacterial overgrowthN (%)Total19 (100)Male**7(36.8)**Age, years (SD)**56.5 (17.6)**Medications**  **Anticholinergics**5 (26.3)  **Calcium channel blocker**3 (15.8)  **Proton pump inhibitor**12 (63.2)**Comorbidities**  **Diabetes mellitus**5 (26.3)  **Sjogren's syndrome**1 (12.5)**Penicillin allergy**3 (15.8)

SIBO Eradication {#Sec13}
----------------

The mean peak hydrogen excretion was 13.68 ± 2.83 and 10.26 ± 7.30 ppm at baseline and following rifaximin treatment, respectively (t = 1.98, p = 0.06). Following treatment with rifaximin, LBT normalized in 8/19 (42.1%) subjects, and LBT recordings decreased in 12/19 (63.2%) subjects. In 7/19 (36.8%) subjects the LBT recording increased or remained unchanged (Figure [2](#Fig2){ref-type="fig"}). No difference in demographic or clinical characteristics was observed between rifaximin responders and non-responders (Table [2](#Tab2){ref-type="table"}). No patients reported any degree of resolution of either bloating or flatulence. No adverse events were reported.Figure 2**Peak Hydrogen Excretion at Baseline and Following Rifaxamin.**Table 2**Demographic and clinical features according to rifaximin responseResponders N (%)Non-responders N (%)*P*** **valueN (%)**8 (42.1)11 (57.9)0.74**Male**2 (25)5 (75)0.37**Age, years (SD)**57.6 (19.5)55.6 (17.1)0.72**Medications**  **Anticholinergics**1 (12.5)4 (36.4)0.31  **Calcium channel blocker**1 (12.5)2 (18.2)1.00  **Proton pump inhibitor**5 (62.5)7 (63.6)1.00**Comorbidities**  **Diabetes mellitus**3 (37.5)2 (18.2)0.61  **Scleroderma**0 (0)0 (0)1.00  **Sjogren's syndrome**1 (12.5)1 (9.1)1.00

Discussion {#Sec14}
==========

In the present study we describe a prospective cohort of subjects receiving the non-absorbable antibiotic rifaximin for LBT-diagnosed SIBO. Treatment success, measured by normalization of LBT, was only 42%. This is the first such study to emanate from our geographical region.

The dosage of rifaximin 1200 mg and the treatment duration of 10 days was chosen in accordance with previous data demonstrating its superior efficacy compared to lower doses \[[@CR18],[@CR19]\]. Rifaximin has a broad spectrum of activity, especially against anaerobic intestinal bacteria, including *Bacteroides*, *Lactobacilli* and *Clostridia*, which are frequently responsible for the metabolic derangements in SIBO patients. Its activity profile resembles rifamycin, however toxicity is low since it is minimally absorbed from the gut \[[@CR20]\].

Previous studies have assessed the efficacy of rifaximin in IBS patients with symptoms compatible with SIBO. Up to 84% of patients with IBS have a positive LBT, suggesting that the etiology and symptom manifestation of IBS and SIBO may overlap \[[@CR4]\]. Pimental, *et al.* in the landmark TARGET trial, randomized IBS patients without constipation to receive rifaximin 1650 mg or placebo for two weeks. Adequate relief of IBS symptoms was reported in 40.8% and 31.2% of treatment and placebo groups, respectively (*p* = 0.01). However, in their study no breath test was performed at baseline or following treatment \[[@CR21]\]. Meyrat, *et al.* treated LBT-positive IBS patients with rifaximin, and demonstrated that treatment was associated with significant improvement in symptoms. LBT negativity was 86% following rifaximin treatment, more than twofold the rate we observed in our non-IBS cohort \[[@CR7]\]. Several other nonrandomized open labeled studies have reported similar results \[[@CR8]-[@CR10]\]. A recently published meta-analysis concluded that rifaximin is, indeed, more efficacious than placebo for global IBS symptom improvement \[OR = 1.57, 95% CI: 1.22--2.01, therapeutic gain 9.8%, number needed to treat (NNT) = 10.2\] \[[@CR12]\].

We can speculate that the efficacy of rifaximin in IBS may be unrelated to SIBO, since IBS patients with a negative baseline LBT appear to experience symptomatic improvement. This concurs with our experience in non-IBS SIBO patients in whom symptom improvement was absent or minimal, and suggests that rifaximin is effective treatment for symptoms of IBS, but not for the normalization of LBT in patients with bloating and flatulence. Nevertheless, the presence of IBS cannot account for the marked discrepancy in LBT normalization rates between our non-IBS cohort and other IBS cohorts. The most likely explanation is related to geographical, dietary or ethnic differences in microbiome \[[@CR22]\].

In addition to IBS, the rate of LBT normalization following rifaximin therapy has been reported in pediatric patients (20-64%) \[[@CR23],[@CR24]\], patients with ileal Crohn's disease (100%) \[[@CR25]\], microscopic colitis (71%) \[[@CR26]\], celiac disease (4%) \[[@CR27]\], chronic acid suppression (87%) \[[@CR6]\], diabetes (86%) \[[@CR28]\], diverticulitis (100%) \[[@CR29]\] and systemic sclerosis (73%) \[[@CR30]\]. Despite the fact that treatment protocols vary widely between studies, and irrespective of clinical endpoints, the efficacy of rifaximin for the treatment of SIBO assessed by LBT is clearly unpredictable. This fact is corroborated by our study. No studies to date have specifically targeted patients with SIBO in the absence of IBS or any of the aforementioned associated comorbid conditions for rifaximin therapy.

Several studies have examined a potential role for pre- and probiotics in combination with rifaximin for the treatment of suspected SIBO. Normalization of LBT is significantly higher in patients who receive rifaximin in combination with prebiotics, compared to rifaximin alone (87.1% *vs.* 62.1%, p = 0.02) \[[@CR31]\]. Sequential treatment of SIBO with rifaximin and probiotics appears more efficacious than rifaximin and prebiotics with respect to symptom reduction \[[@CR32]\]. In fact, some centers recommend sequential treatment with rifaximin followed by probiotics as a standard approach to treating SIBO \[[@CR8]\].

Our study has several important limitations, including its small size, and open label design. Our power analysis indicated that 22 subjects needed to be recruited, however this was based on the assumption that at least 50% of subjects treated with rifaximin would have a normal LBT at follow-up. In retrospect, 50% was a slight overestimation, as normalization was actually achieved in 42.1% subjects. We did not include a thorough clinical evaluation or screening period, and therefore no conclusions can be drawn regarding the effect of rifaximin on symptoms. Nevertheless, as a laboratory-based study, our results are valid insofar as they demonstrate that rifaximin does not consistently normalize LBT in SIBO patients. A further limitation of our study is related to the ongoing controversy regarding the validity and interpretation of LBT in SIBO. Some clinicians do not regard LBT as the de facto gold standard for the diagnosis of SIBO, and demand indirect supportive evidence including serum vitamin B12 levels and folate levels \[[@CR16],[@CR33]\]. Inherent problems with LBT include difficulty in distinguishing SIBO from rapid intestinal transit where similar gas production patterns are observed (false positivity) \[[@CR3]\]. In fact, it has been suggested that LBT positivity in IBS patients may be related to rapid intestinal transit, and not SIBO \[[@CR34]\]. Finally, compliance was not assessed with pill counts or used packages. Nevertheless, due to the high cost of rifaximin treatment in Israel, we presume that compliance was high.

In conclusion, although most subjects with SIBO who were exposed to rifaximin experienced a reduction in peak hydrogen excretion, this reduction lacked statistical significance. Rifaximin eradicated SIBO in fewer than half of treated patients. Larger studies in non-IBS populations are necessary to verify our findings. Further research should consider both clinical and laboratory endpoints, and explore a potential role for pre- and probiotics in the treatment of SIBO.
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